Integrating people-centered HIV care with primary health care is essential to improving access, equity and health outcomes, but doing so successfully requires coordinated policies, digital ...

While people living with HIV can lead virtually normal lives thanks to antiretroviral therapy (ART), HIV persists in a latent ...

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

As HIV cases continue to rise in the Philippines, especially among the youth, a new global development may offer hope in ...

In the ongoing fight against HIV, scientists have taken a new step toward long-term control of the virus. Researchers have ...

Innovative, nontoxic molecules developed by a research team at the Institut national de la recherche scientifique (INRS) ...

In order to meet the biological constraints, In this paper we consider a system of four equations which captures T-cell-HIV interactions. It describes the behavior of normal T cells, latently-infected ...

Acquired immune deficiency syndrome, or AIDS, caused by the human immunodeficiency virus (HIV), weakens the body's immune ...

In a study of human immune cells infected with HIV, the virus that causes AIDS, scientists at Johns Hopkins Medicine say a molecule within HIV itself can be manipulated and amplified to force the ...

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah biochemist whose discoveries helped make the drug happen worries government cuts ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence rates compared to other PrEP medications and with minimal side effects.